Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.

about

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.

Item

http://www.wikidata.org/entity/Q39413114

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Hypomethylating agents (HMA) t ...... rontline and relapse settings.

@en

Hypomethylating agents

@nl

type

Item

label

Hypomethylating agents (HMA) t ...... rontline and relapse settings.

@en

Hypomethylating agents

@nl

prefLabel

Hypomethylating agents (HMA) t ...... rontline and relapse settings.

@en

Hypomethylating agents

@nl

P1476

Hypomethylating agents (HMA) t ...... rontline and relapse settings.

@en

P2093

Abhay Singh

http://www.w3.org/2001/XMLSchema#string

Natalie Uy

http://www.w3.org/2001/XMLSchema#string

Steven D Gore

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations

Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

International scoring system for evaluating prognosis in myelodysplastic syndromes

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

P304

1213-1224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1349100

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Prebet

P577

2017-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28675065

http://www.w3.org/2001/XMLSchema#string

P932

6121132

http://www.w3.org/2001/XMLSchema#string